Copenhagen, 2014-10-27 16:06 CET (GLOBE NEWSWIRE) -- Exiqon A/S (NASDAQ Copenhagen: “EXQ”) today announced the expected dates for Exiqon A/S’ annual general meeting and financial reporting in 2015.
| Announcement of full-year results 2014: | 30 January 2015 |
| Deadline for shareholders’ proposal to the annual general meeting: | 05 February 2015 |
| The annual general meeting is scheduled to be held on: | 19 March 2015 |
| Interim report for the period 1 January 2015 to 31 March 2015: | 07 May 2015 |
| Interim report for the period 1 January 2015 to 30 June 2015: | 25 August 2015 |
| Interim report for the period 1 January 2015 to 30 September 2015: | 26 October 2015 |
Additional information
Lars Kongsbak, President and CEO, tel. +45 4566 0888 (cell: +45 4090 2101)
Hans Henrik Chrois Christensen, CFO, tel. +45 4566 0888 (cell: +45 4090 2131)
About Exiqon
Exiqon operates in two business areas. Exiqon Life Sciences is a leading provider of flexible solutions for RNA analysis. Exiqon Life Sciences’ research products are used by academia, biotech and pharmaceutical companies around the world to make groundbreaking discoveries about the correlation between gene activity and the development of diseases. Exiqon Diagnostics collaborates with pharmaceutical and diagnostic companies to develop novel molecular diagnostic tests for early detection of diseases which can help physicians make treatment decisions based on the tools developed by Exiqon Life Sciences. Exiqon is listed on NASDAQ Copenhagen. For more information about us, please visit www.exiqon.com
